53332-79-9 Usage
Description
(1-METHYL-1H-BENZIMIDAZOL-2-YL)METHYLAMINE DIHYDROCHLORIDE is an organic compound with the chemical structure of a benzimidazole core, featuring a methyl group and an amine functional group. It is a white crystalline solid and is commonly used as a building block in the synthesis of various chemical compounds, particularly in the pharmaceutical and chemical industries.
Uses
Used in Pharmaceutical Industry:
(1-METHYL-1H-BENZIMIDAZOL-2-YL)METHYLAMINE DIHYDROCHLORIDE is used as a key intermediate in the synthesis of benzimidazolyl Schiff base ligands for the development of new pharmaceutical compounds. These ligands have potential applications in the treatment of various diseases, including cancer, due to their ability to form stable complexes with metal ions and modulate biological activities.
Used in Chemical Industry:
In the chemical industry, (1-METHYL-1H-BENZIMIDAZOL-2-YL)METHYLAMINE DIHYDROCHLORIDE serves as a versatile building block for the synthesis of a wide range of organic compounds, such as dyes, pigments, and other specialty chemicals. Its unique chemical structure allows for various functional group transformations and reactions, making it a valuable component in the development of novel materials and products.
Check Digit Verification of cas no
The CAS Registry Mumber 53332-79-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,3,3,3 and 2 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 53332-79:
(7*5)+(6*3)+(5*3)+(4*3)+(3*2)+(2*7)+(1*9)=109
109 % 10 = 9
So 53332-79-9 is a valid CAS Registry Number.
53332-79-9Relevant articles and documents
BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS
-
Page/Page column 37, (2008/06/13)
The present invention provides compounds having formula (I) wherein n, p, q and r are each independently selected from 0 or 1; a, b, c, and d each independently represents a carbon or nitrogen atom, with the proviso that no more than two of a, b, c, and d are nitrogen atoms; Y and Y' each independently represents 1-4 optional substituents selected from alkyl, alkoxy, halo, -CF3, and -C(O)OH; R, R, R and R are H or specified substituents; R, R, R, R, R, R, R and R are independently selected from H or C1-C3 alkyl; or a biolabile ester thereof, or a pharmaceutically acceptable salt thereof. Also provided are methods of using these compounds for treating vitronectin-mediated disorders, e.g., cancer, retinopathy, artherosclerosis, vascular restenosis, and osteoporosis.
Benzimidazole compounds that are vitronectin receptor antagonists
-
, (2008/06/13)
The present invention provides compounds having the formula wherein n, p, q and r are each independently selected from 0 or 1; a, b, c, and d each independently represents a carbon or nitrogen atom, with the proviso that no more than two of a, b, c, and d
